Default company panoramic image

Innate Architects

A new dimension of immunoprophylaxis. Lead indication perioperative prophylaxis - a pressing public health problem and healtheconomic issue

Company Summary

Value generation through preclinical and early clinical development of a novel immunoprophylaxis for the prevention of severe and life-threatening conditions without viable alternatives, addressing public health concerns and healtheconomic issues, with market potential >1 bn $. Partnering of development programs with big pharma providing attractive returns to investors.


  • Default avatar
    Julian Wagner

    >10 Years experience in immunotherapy and vaccine R&D; previously Manager Business Development & Market Access at Pevion Biotech (5 years) and Founder/Partner of two start up projects. Education in biochemistry and business administration.

  • Default avatar
    Matthias Kaeser

    >12 Years professional experience; currently Scientist DSP & Virosomal Technology at Crucell Switzerland (Johnson&Johnson); previously Deputy Head Process Development at Pevion Biotech (5 years) and Research Associate at the Salk Institute, La Jolla. Education in biochemistry.

  • Default avatar
    Patrice Dubois

    28 Years experience in immunology, thereof 15 in vaccine R&D; since 2009 serving at the WHO-collaborating Vaccine Formulation Laboratory at the University of Lausanne; previously freelance consultant and Senior Scientist at GSK Biologicals.